Shwetal Mehta, Ph.D. (she/her)
@smehtalab
Followers
443
Following
3K
Media
69
Statuses
405
Professor, Barrow Neurological Institute Deputy Director, Ivy Brain Tumor Center
Arizona, USA
Joined December 2010
Sonodynamic therapy involving focused ultrasound and systemic 5-ALA is safe in patients with recurrent #glioma and shows preliminary signs of biological efficacy, according to a new pilot trial. @smehtalab @NaderSanai @IvyBrainTumCtr
https://t.co/NH3jxnDQ34
0
5
10
So excited to get this paper out! Just in time for Thanksgiving. So very grateful to our patients and their families🙏🏼 An early clinical trial of 5-ALA sonodynamic therapy in recurrent high-grade glioma | Science Translational Medicine https://t.co/hFCraWYzVz
@IvyBrainTumCtr
science.org
An early clinical study demonstrates feasibility of noninvasive 5-ALA sonodynamic treatment in nine patients with recurrent high-grade glioma.
0
0
5
Our PK-triggered Phase 0 hybrid trials require extensive assay development and validation. Today Dr. Karapetyan is presenting two posters from @IvyBrainTumCtr on PK assay validation for EGFR inhibitor BDTX-1535 and mTOR inhibitor, Temsirolimus. #AACR2025
0
1
6
Two posters from @IvyBrainTumCtr were presented at the AACR annual meeting by @AnChiTien and Jocelyn Harmon on our ongoing Phase 0/1 trial for EGFR inhibitor (BDTX-1535) in recurrent GBM patients and Factors influencing participant attrition in Phase 0 hybrid trials. #AACR2025.
1
2
14
Susan Histed presenting first of five posters being presented at the AACR Annual Meeting from @IvyBrainTumCtr. Her work focuses on preclinical drug combination studies in glioma models. #AACR2025
0
3
12
Dr Larry Salzman, a physician and cancer survivor emphasized the importance of accessible clinical trials and cancer research for bringing new treatment options for cancer patients upon receiving the Distinguished Public Service award. #AACR2025
Opening plenary at #AACR25 Dr Pat LaRusso honors Dr Larry Salzman with the Distinguished Public Service Award. Thank you Dr Salzman for your fierce advocacy for medical research for life threatening diseases.
0
0
5
.@YoshieUmemura from @IvyBrainTumCtr presenting our PK/PD data from Phase 0/1 trial of AZD1390 which provides support for a phase 2/3 trial. #sno2024
0
1
17
So honored to get the opportunity to present these data on behalf of our incredible team @IvyBrainTumCtr @BarrowNeuro #SNO2024
Insightful presentation by Dr. @smehtalab on Phase 0/2 trial of abemaciclib + LY3214996 in rGBM, showing relevant drug levels but CNS penetration challenges. Don't miss Dr. @YoshieUmemura's talk on our Phase 0/1b trial of AZD1390 in #GBM tomorrow at #SNO2024! @NeuroOnc
0
0
14
Stop by tonight at @AnChiTien ‘s poster on our Phase 0/1 trial with 4th generation EGFR inhibitor in rGBM patients #SNO2024 @IvyBrainTumCtr @BarrowNeuro
Dr. An-Chi Tien presents compelling results from our Phase 0/1 study of BDTX-1535 in recurrent GBM patients with EGFR alterations at #SNO2024. The poster reveals that BDTX-1535 is well-tolerated, achieves pharmacologically relevant concentrations in non-enhancing tumor tissue,
0
0
15
I had a great time attending and presenting at the @CUCancerBio retreat this weekend. Fantastic talks from the students and faculty. Thank you to the organizers for inviting me @morgan_fox_ @EllenBamberg and others. It was great catching up with @cittelly and @mitralabcuamc
0
2
11
🎉 Congratulations to Dr. Nader Sanai, director of the Ivy Center, for being named the 2024 Arizona Bioscience Researcher of the Year! Dr. Sanai will receive this award at the 20th Annual @AZBio Awards on Sept. 18. 📰: https://t.co/xxgUrc2EIl
1
3
8
So great to have three of @IvyBrainTumCtr researchers be part of this amazing @abta community. @AnChiTien @charutafurey and Artak Tovmasyan 👏🏻🧠
Exciting things are happening at the #ABTANationalConference! 🎉 Our amazing AARN members—leading brain tumor researchers—are here sharing groundbreaking ideas and innovations that bring us closer to finding a cure! 🙌💡🧠 #BrainTumorResearch #MeetHopeHeadOn #CureBrainTumors”
0
3
18
As we celebrate the approval of vorasidenib for treatment of grade II IDH-mutant, I would like to recognize those that developed the original compounds. See https://t.co/38HCJgegUc,
https://t.co/Clj7dXFGZW and perhaps most importantly https://t.co/AfN36y1TZP. Fantastic job!
pubs.acs.org
Optimization of a series of R132H IDH1 inhibitors from a high throughput screen led to the first potent molecules that show robust tumor 2-HG inhibition in a xenograft model. Compound 35 shows good...
4
23
85
Next week, we will send off 38 summer research interns @BarrowNeuro with a research symposium packed with student presentations, posters and a keynote speaker who has been my mentor for 25 years! I could not be more excited to welcome Dr. Huganir @rhuganir to Barrow!
0
5
17
It has been such a pleasure to work with @amyyhong @IvyBrainTumCtr over the last five years! She is our go to person when it comes to any data management questions! Looking forward to many more collaborative years, Amy! 👏🏻💪🏼
For the last five years, Amy has been the backbone of our data management team and a core clinical operations team member, helping us achieve new levels of success and innovation. 🌟 Please help us congratulate Amy on all that she has accomplished and contributed! 🎉
0
0
7
Congratulations @MylanBlomquist and Nhan Tran @MayoClinic for your paper on EGFRvIII- and STAT5-dependent sensitivity to Saracatinib treatment in #GBM
https://t.co/hDRV4397VT
mdpi.com
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with few effective treatments. EGFR alterations, including expression of the truncated variant EGFRvIII, are among the...
0
1
4
So excited to get these data out finally. It has been such a pleasure working with @roelverhaak @Kevin_C_Johnson and team! Key take aways - CDK4/6i treatment results in cell state change that is reproducible in vitro and no brain penetration or PD effect seen for Everolimus
Happy to share results from a new Phase 0 trial led by @IvyBrainTumCtr @NaderSanai @smehtalab and @Kevin_C_Johnson: Single nucleus transcriptomics, PK/PD of combined CDK4/6 and mTOR inhibition in a phase 0/1 trial of recurrent high-grade glioma
0
0
13
At the Ivy Center, our dedication is to find a cure for brain cancer. On #WorldBrainTumorDay, we continue to push boundaries in brain tumor research to discover new, more effective therapies. Join us in raising awareness in the fight against brain tumors. 🌏🧠
0
2
8